Clinical Trials Logo

Filter by:
NCT ID: NCT04310774 Not yet recruiting - Cervical Cancer Clinical Trials

CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer

Start date: April 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single institute, single-arm, interventional trial to evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy in patients with locally advanced cervical cancer.

NCT ID: NCT04313309 Not yet recruiting - Clinical trials for Chronic Musculoskeletal Pain

Evaluating Chronic Pain Management Program

Start date: April 15, 2020
Phase: N/A
Study type: Interventional

This interventional study seeks to evaluate the overall outcomes of a novel, integrated yoga based intervention for people with chronic musculoskeletal pain and assess the experience of patient to the self care using yoga practices.

NCT ID: NCT04314154 Not yet recruiting - Schizophrenia Clinical Trials

Using Clinical Process Indicators, Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) to Improve the Quality and Continuity of Care for Psychiatric Patients

PROM-PREM
Start date: April 15, 2020
Phase:
Study type: Observational

The objective of the proposed study is to take a further step in this direction by developing, implementing and monitoring a routine systematic evaluation of clinical process and outcome indicators, patient reported experience (PREMs) and patient reported outcomes (PROMs) to study the quality and continuity of care over time.

NCT ID: NCT04320134 Not yet recruiting - Atrial Fibrillation Clinical Trials

cliNIcal sCEnarios and Pathophysiology of Atrial Fibrillation

NICE-AF
Start date: April 15, 2020
Phase:
Study type: Observational [Patient Registry]

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia with prevalence and incidence continuously increasing worldwide. Current guidelines propose an etiological, symptom-based classification of the arrhythmia and mainly focused on its duration with consequent rhythm or rate-control strategies. Moreover, risk scores for atherothrombotic systemic or hemorrhagic events related to atrial fibrillation are principally based on patients cardiovascular history and risk factors. This approach do not consider relevant pathophysiological aspects that may play a pivotal role in triggering or perpetuating the arrhythmia, especially at its first occurrence. At this point, a crucial step would be deeply investigating AF clinical and pathophysiological features to guide a tailored diagnostical and therapeutic approach. Indeed, early recognition and proper characterization of triggers, substrates, autonomic system imbalance and modulating factors (drugs, electrolytes, etc) are of the utmost importance for AF care and management. Therefore, this large scale prospective observational study aims to evaluate clinical and pathophysiological features of patients with symptomatic and asymptomatic atrial fibrillation in different scenarios to understand possible distinctive characteristics warranting a personalized approach to the arrhythmia.

NCT ID: NCT04332562 Not yet recruiting - Clinical trials for Hypertension, Essential

The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension

BHB-RCT
Start date: April 15, 2020
Phase: N/A
Study type: Interventional

In this research the investigators are looking for the direct relationship between Beta-hydroxybutyrate and hypertension. Since recent research showed a connection between exercise and hypertension, and diet control and hypertension. The investigators are studying the possible effect of beta-hydroxybutyrate levels on blood pressure control.

NCT ID: NCT04336865 Not yet recruiting - Contraception Clinical Trials

Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Start date: April 15, 2020
Phase:
Study type: Observational

Effect of hormonal contraception on lower urinary tract symptoms& sexual function

NCT ID: NCT04338386 Not yet recruiting - Multiple Myeloma Clinical Trials

Detection and Pathogenesis of Novel Protein F

Start date: April 15, 2020
Phase:
Study type: Observational

From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

NCT ID: NCT04341831 Not yet recruiting - Clinical trials for Lumbar Spinal Stenosis

Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection

Start date: April 15, 2020
Phase: Phase 3
Study type: Interventional

Infection after spinal surgery is one of the serious complications. Spinal surgery infection can cause high morbidity, mortality, and costs. In spite of different prophylactic methods, up to 15% of infection appears after spinal surgery. Vancomycin powder, which is one of the most applied methods, seems to be effective and inexpensive. However, vancomycin administration may be inconvenient in elderly participants with high comorbidity and especially kidney problems. The investigators aimed to reduce the rate of infection in the post-op 90-day period by adding per-op Teicoplanin powder onto the implant in participants scheduled for lumbar posterior instrumentation.

NCT ID: NCT04343144 Not yet recruiting - Clinical trials for COVID19- Infection With SARS-CoV-2 Virus

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

CORIMUNO-NIVO
Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

It appears interesting to use nivolumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU. This protocol CORIMUNO19-NIVO therefore, will evaluate the efficacy and safety of OPTIVO® (nivolumab) COVID-19 patients hospitalized in conventional unit. The purpose of this study is to show the efficacy of nivolumab in patients with COVID-19 in combination with standard treatments. A phase 2 randomized open trial will evaluate the efficacy and safety of optivo® (nivolumab) alone versus standard of care (SoC) in patients hospitalized in conventional units. Patients will be randomly allocated 1:1 to either nivolumab or SoC.

NCT ID: NCT04344782 Not yet recruiting - COVID19 Pneumonia Clinical Trials

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

CORIMMUNO-BEVA
Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU. This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) COVID-19 patients hospitalized in conventional units. This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.